PolyPid (PYPD) Stock Analysis

What PolyPid does

PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.

Key metrics

ETFs linked to PYPD

Broad-market and Healthcare sector ETFs an investor holding PolyPid is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PYPD fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for PolyPid?

PolyPid trades under the ticker PYPD on NASDAQ.

Which exchange is PYPD listed on?

PYPD is listed on NASDAQ.

What sector does PolyPid operate in?

PolyPid is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PYPD in a portfolio?

PortView shows PYPD's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.